Scisparc receives approval to conduct phase iib clinical trial for sci-110 to treat tourette syndrome in germany

The federal institute for drugs and medical devices in germany granted the company approval to use sci-110 in a clinical trial at the hannover medical school

SPRC Ratings Summary

SPRC Quant Ranking